Background: Capsular contracture (CC) is the most frequently reported complication following breast augmentation. A growing body of evidence implicates subclinical (biofilm) infection around breast implants as an important cause of CC; however, effective prophylactic and treatment modalities remain controversial. Objectives: This article aims to review a single surgeon's experience using an antibiotic-impregnated mesh as a prophylactic measure against biofilm formation and recurrent CC. Methods: This study retrospectively reviewed 5 consecutive patients presenting with CC (Baker grades III and IV) who were managed by capsulectomy with implant replacement and simultaneous insertion of an antibiotic-impregnated mesh. Patient demographics and major complications were recorded, including CC recurrence, reoperation, and infection. Results: Complete correction of the contracture with no recurrence was achieved in all patients at a median followup of 25 months. Conclusions: This study demonstrates a novel technique using an antibiotic mesh to reduce bacterial access to breast implants at the time of insertion. Further investigation is warranted with more clinical cases in order to recommend this technique for the management of subclinical infection and CC.
implant-associated anaplastic large cell lymphoma (BIA-ALCL), 11, 12 an effective antimicrobial prophylactic strategy may have the potential to greatly impact 2 of the most serious complications of breast augmentation surgery.
A study performed by Jacombs et al 13 demonstrated that the use of an antibiotic-impregnated mesh inserted under implants in a porcine model had a clear protective effect against the development of biofilm formation and subsequent contracture. There were multiple limitations to these findings. Namely, the harvesting of the breast implants at 16 weeks precluded longer followup to determine whether any of the treated implants would progress to contracture. Furthermore, the efficacy of the antibacterial envelope for CC prophylaxis has yet to be established in a human model.
In this study, we undertook a retrospective analysis of a series of 5 consecutive patients presenting with CC following breast augmentation who were treated with the TYRX™ (TYRX, Inc., Monmouth Junction, NJ) minocycline and rifampin-eluting antibacterial envelope at the time of capsulectomy and implant replacement. The purpose of this study was to assess the effectiveness of this novel technique in preventing CC recurrence.
METHODS
We performed a retrospective analysis of 5 consecutive patients presenting with CC following breast augmentation from July 2015 through February 2017. All 5 patients were managed by capsulectomy through an inframammary incision with implant replacement into the submuscular plane, as described by Melmed. 14 The simultaneous insertion of a TYRX™ absorbable antibiotic-impregnated polypropylene mesh anterior to the implant, adjacent to the breast parenchyma was performed in all patients (Video). The absorbable mesh was not stabilized to any surrounding tissue, as its sole purpose was to serve as an absorbable antibiotic delivery system. The senior surgeon (M.R.) adhered to standard protocol, using triple antibiotic solution of bacitracin (50,000U)/vancomycin (1 g)/gentamycin (80 mg) for irrigation in 500 cc of normal saline. Each pocket received 250 cc of irrigation. Each implant was soaked in triple antibiotic solution prior to opening the packaging by puncturing the paper with a blunt needle and injecting the solution into the packaging container under direct visualization without damaging the implant. Implants were inserted using a "no touch" atraumatic technique with the Keller Funnel. Prior to closure, all pockets were rinsed with 50% triple antibiotic solution and 50% betadine paint solution. All patients received Tegaderm™ (3M Health Care, Two Harbors, MN) nipple shields.
All 5 patients were available for review at a median followup of 25 months and were included in the study. Each sheet of mesh measured 7.4 cm × 8.5 cm and contained approximately 7.6 mg minocycline and 11.9 mg rifampin. Each sheet was cut in half; therefore, each breast capsule received approximately 3.8 mg minocycline and 5.95 mg rifampin. Institutional review board approval was not undertaken. The study conformed to the guidelines of the Department of Health and Human Services Regulations for the Protection of Human Subjects, 15 and informed consent was obtained from all patients. The off-label use of the mesh, specific risks and benefits, and right to decline to take part in the study were discussed at length with all patients.
Demographic data obtained included age, BMI, laterality, Baker grade, duration of original implant, new implant type, and followup months. Postoperative outcomes obtained included CC recurrence, re-operations, infection, and complications.
RESULTS
The mean age at presentation was 47.0 ± 7.3 years (range, 35-54 years). The median BMI was 21.5 kg/m 2 (range, 18.4-36.4 kg/m 2 ). One patient (20%) presented with Baker grade III CC, and 4 patients (80%) with Baker grade IV. Two patients (40%) had a history of prior CC and implant revision at outside clinics. One patient (20%) presented with unilateral (right) CC (Figure 1 ), and 4 (80%) presented with bilateral CC. A total of 9 mammary augmentations utilizing the antibiotic-impregnated mesh were performed on 5 patients. Demographic data are outlined in Table 1 .
There was no recurrence of CC, development of suture site infection (SSI), or reoperation at a median followup of 25 months (range, 10-29 months). One patient (20%) developed a small hematoma of the right breast on POD 1, which required surgical evacuation. Patient outcomes are summarized in Table 2 . 
DISCUSSION
The TYRX™ absorbable antibacterial envelope is currently indicated for stabilization of cardiovascular implantable electronic devices (CIED), such as pacemakers or defibrillators. 16 The envelope releases rifampin and minocycline over a period of 7 to 10 days and has been shown to reduce CIED infection in large multicenter clinical studies. [17] [18] [19] [20] A retrospective cohort study by Kolek et al analyzed CIED infection rates in patients receiving the antibacterial envelope vs a matched control cohort. After a minimum of 90 days of followup, there was one CIED infection among patients who received an antibacterial envelope (0.4%), compared to 19 (3%) in controls (odds ratio [95% confidence interval] 0.13 [0.02-0.95], P = 0.04). While this envelope has been utilized primarily in cardiothoracic surgery, as plastic surgeons, we are among the leading users of prostheses in surgery, and it is important that we are kept informed of the increasing evidence that bacterial biofilm is responsible for the failure of medical devices, and ways in which we can prevent this from occurring. Biofilm formation follows a developmental progression involving 4 stages: reversible attachment, irreversible attachment, growth and differentiation, and dissemination. The presence of subclinical infection as a cause of capsular contracture around breast implants was first postulated by Burkhardt et al, who subsequently recommended betadine pocket irrigation to reduce the risk of bacterial contamination. 9 In vitro studies have shown that bacteria are able to bind to the surface of breast implants, regardless of surface texture, and animal models have confirmed that seeding of bacteria onto breast implants can lead to biofilm formation and subsequent contracture. As a result, it is imperative that antimicrobial coating agents currently being used for other medical implants should be investigated as novel preventative solutions to CC. The TYRX™ antibacterial envelope has been shown in porcine models to reduce bacterial access to breast implants at the time of insertion, resulting in a protective effect against the development of biofilm formation. 13 In a study carried out by Jacombs et al, researchers implanted a total of 28 prostheses into 5 pigs. All 28 implants and their pockets were inoculated with Staphylococcus epidermidis isolated from a human patient with CC. Fourteen implants were inserted with antibiotic mesh (treatment), and the other 14 were untreated (control). All untreated implants developed Baker grade III/IV CC. In contrast, all treated implants were grade I/II after 16 weeks, (P < 0.001). Specimens with CC had at least 10-fold higher bacterial counts. Bacterial colonization of mesh-covered implants was typically single layered, if present. In contrast, multilayered biofilms were detected in all untreated implants. In preclinical studies, the TYRX™ envelope demonstrated antimicrobial activity against multiple bacteria, including S. epidermidis, 21 which has been established as one of the main contributors to biofilm formation and subsequent CC. 22 Combining sound evidence from multiple in vivo and clinical studies suggests the off-label use of this antibacterial envelope to prevent CC is a safe and logical application warranting clinical evaluation.
Numerous studies have outlined operative strategies aimed at reducing the risk of bacterial contamination at the time of implant insertion. Surgical site irrigation is one of these commonly employed strategies; however, evidence-based guidelines for the composition of irrigation solutions and time of local exposure are lacking. In a study by Hu et al, 23 the efficacy of PhaseOne, a hypochlorous-acid-containing irrigant, was tested in vitro against betadine containing 10% povidone iodine. Findings showed that povidone-iodine-containing irrigants are superior to hypochlorous-acid-containing irrigants in the clinical setting and should remain the recommended solution for pocket irrigation to reduce bacterial contamination in breast implant surgery. A recent study by Zhadan et al 24 found that the optimal wound irrigation agents for surgical site infection prophylaxis were 0.05% chlorhexidine or triple antibiotic solution. This study was the first to report the effectiveness of different antibiotic solutions depending on exposure time of the irrigation agents. Importantly, they found that prolonged irrigation time was necessary to achieve sterility of the in vitro model of the surgical site. However, the 30-minute window of open-wound irrigation in the operating room will not be convenient for surgeons, as well as not economically justified from the OR time use point of view. This highlights the potential benefit of utilizing an antibacterial envelope for prolonged bacterial control past this initial timeframe. Given that the management of a seeded implant is exponentially more difficult than the management of a routine postoperative infection, prevention is paramount. These studies taken together highlight that prevention of biofilm formation in its early stage using antibiotic coating of implants, rather than treating biofilm-related infections, would be more desirable in a clinical setting and thus warrant further research into the effectiveness of the method presented in this study. In a study performed by Hu et al, 12 BIA-ALCL clinical samples revealed high numbers of bacteria analogous to the number of bacteria found in specimens obtained from patients with CC. Interestingly, they also showed that the microbiome in these tumor samples was significantly different from the microbiome around non-tumor CC specimens, suggesting that different bacterial species may preferentially trigger lymphocyte activation. Specifically, they found a significantly greater proportion of Ralstonia spp. present in the ALCL specimens compared with nontumor capsule specimens. Ralstonia spp. are being increasingly recognized as a pathogen causing serious soft-tissue and implant-related infections, and may not be adequately covered in current prophylactic antibiotic regimens. 25, 26 The TYRX™ mesh used in our study contains minocycline, which has been shown to be effective against nearly all isolates of Ralstonia. 27 In light of research carried out by Kadin et al 28 showing that specific patterns of cytokine and transcription factor expression suggest that BIA-ALCL is likely to arise from chronic bacterial antigen stimulation of T-cells, our simple method utilizing the TYRX™ mesh could be of benefit not only in the prevention of CC, but against BIA-ALCL as well. While we cannot draw any significant conclusions regarding the effect of an antibacterial envelope on prevention of CC, the potential implications regarding BIA-ALCL make further study of our method more fascinating and widely applicable.
Francolini et al 29 advocated that antibiofilm strategies should be based on: 1) inhibition of microbial adhesion to the surface and of colonization; 2) interference with the signal molecules modulating biofilm development; and 3) disaggregation of the biofilm matrix. While the TYRX™ antibacterial mesh conforms to this concept, one must recognize the limitations present in our study. For example, antibiotic impregnated devices could potentially lead to selection of resistant bacteria due to the altered physiological state of bacteria in the biofilm microenvironment. The antibiotics released from the mesh, rifampin, and minocycline have been shown to be effective in treating S. epidermidis; however, they may not be effective in all cases. Furthermore, studies have implicated a number of other bacteria in the formation of biofilm on breast implants that may not be as susceptible to these antibiotics as S. epidermidis. 5, 30 We did not include analysis of the mesh alone, without antibiotic impregnation, and are therefore unable to exclude local protective or inflammatory effects. Additionally, although the drug diffusion activity of the mesh seems to be effective at reducing bacterial contact around the time of implantation up to 7-10 days, it is important to recognize that CC may develop at any postoperative time point, with rates continuing to increase over time. Studies performed by Bartsich et al and Urbaniak et al have demonstrated that the clean-contaminated breast pocket harbors endogenous bacteria that can become the source of spontaneous infection, and may even play a role in breast cancer progression. 31, 32 Biofilm formation and CC are long-term phenomena and multifactorial; therefore, strategies associated with protecting breast implants should focus on how to best manipulate the breast microbiome for an extended period of time in order to prevent these processes from occurring. Further studies will be needed in order to elucidate appropriate choice of antibiotics included in the mesh, as well as proper antibiotic dosing.
Though our retrospective study lacks the statistical power necessary to demonstrate an evidence-based solution for preventing CC, we believe it offers a promising technique that warrants further study with a larger number of cases and a control group. This study demonstrates a safe, simple, and relatively inexpensive surgical technique that has shown positive results in a small preliminary cohort of patients. The authors feel the findings should be demonstrated in a larger, protective, ideally randomized trial with a longer followup duration in order to draw statistically significant conclusions and validate its efficacy. Further study of this technique could help to elucidate pathophysiological mechanisms underlying the processes of biofilm formation and CC, as well as provide a novel treatment for this common complication of breast augmentation surgery.
CONCLUSION
In this article we evaluate a series of 5 patients presenting with CC who received insertion of an antibiotic-impregnated polypropylene mesh in conjunction with capsulectomy and implant replacement. None of the 5 patients (0%) demonstrated recurrence of CC, development of SSI, or reoperation at a median followup of 25 months. Though a small series, these data demonstrate a novel technique that may be used as an effective measure to minimize the recurrence of CC. Further investigation is warranted with more clinical cases in order to recommend this technique for the management of subclinical infection and CC.
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